Clinical trials: Neurodevelopmental Outcomes
- Condition Neurodevelopmental Outcomes
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Vestibular Disorder, Educational Problems
VestibulOTherapy: Vestibular Impact on Learning
Research Question: Will daily engagement in activities tailored to the evidence-based vestibular research result in improved attention and learning outcomes for children ages 6-9 years of age after an 8-week classroom-based…
- Conditions
- Vestibular Disorder, Educational Problems, Attention Deficit Disorder
- Trial name
- NCT05793216
- Testing
- VestibulOTherapy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VestibulOTherapy
Children18-72 Months With a Suspicion Autistic Disorder
Extension for Community Healthcare Outcomes (ECHO) Autism Diagnostic Study in Primary Care Setting
This is a collaborative study that will provide a comprehensive source of observational data that can be used to obtain real world evidence of ASD.
- Trial name
- NCT05223374
- Testing
- Canvas Dx
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Cognoa, Inc.
Attention-Deficit/Hyperactivity Disorder
Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes
The purpose of this study is to assess whether changes in the symptoms of ADHD show a relationship with changes in functioning in children with ADHD treated with atomoxetine over a 3-month period.
- Trial name
- NCT00191633
- Testing
- Atomoxetine
- Where
- 19 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Child Behavior Disorders
Using Mobile Technology to Enhance Multisystemic Therapy (MST) Outcomes
The goal of the current trial is to assess the feasibility of a newly developed prototype of a cell phone app called VillageWhere.
- Trial name
- VillageWhere (NCT02320903)
- Testing
- VillageWhere App
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Child Behavior Disorders
VillageWhere: Innovative Mobile Technology for Youth With Conduct Disorder and Their Parents
The goal of this Phase II Small Business Innovation Research (SBIR) is to develop, evaluate, and commercialize a linked parent-youth mobile app system, VillageWhere, to support the key treatment targets of evidence-based…
- Trial name
- VillageWhere (NCT03065517)
- Testing
- VillageWhere App
- Where
- United States
- Volunteers
- 226 people
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
Attention Deficit Hyperactivity Disorder
Community-based Study Comparing Extended-release Methylphenidate and Atomoxetine in Children With Attention-deficit Hyperactivity Disorder
The purpose of this study was to better understand the treatment outcomes of extended-release methylphenidate and atomoxetine in children with attention-deficit hyperactivity disorder (ADHD) as evaluated by physicians and parents…
- Trial name
- NCT00866996
- Testing
- Methylphenidate extended-release; Atomoxetine
- Volunteers
- 1,323 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Attention Deficit Hyperactivity Disorder
Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a two-arm, parallel, randomized, double-blind, placebo-controlled Phase 4 multicenter trial to compare the whole day efficacy of atomoxetine versus placebo in children aged 6 through 12 years with…
- Trial name
- NCT00546910
- Testing
- Atomoxetine
- Where
- 16 sites in Germany
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to evaluate the safety and efficacy of Osmotic Release Oral System (OROS) methylphenidate in participants with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- NCT01012622
- Testing
- Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride
- Volunteers
- 142 people
- Sponsor
- Janssen Korea, Ltd., Korea